Switch theme
Sign up to access all valuation multiples
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
2007
181
LTM Revenue $9.8M
LTM EBITDA -$185M
-$18.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fate Therapeutics has a last 12-month revenue (LTM) of $9.8M and a last 12-month EBITDA of -$185M.
In the most recent fiscal year, Fate Therapeutics achieved revenue of $13.6M and an EBITDA of -$177M.
Fate Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fate Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | XXX | $13.6M | XXX | XXX | XXX |
| Gross Profit | $9.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$185M | XXX | -$177M | XXX | XXX | XXX |
| EBITDA Margin | -1875% | XXX | -1295% | XXX | XXX | XXX |
| EBIT | -$197M | XXX | -$196M | XXX | XXX | XXX |
| EBIT Margin | -2004% | XXX | -1435% | XXX | XXX | XXX |
| Net Profit | -$179M | XXX | -$186M | XXX | XXX | XXX |
| Net Margin | -1822% | XXX | -1366% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fate Therapeutics's stock price is $1.
Fate Therapeutics has current market cap of $139M, and EV of -$18.4M.
See Fate Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$18.4M | $139M | XXX | XXX | XXX | XXX | $-1.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fate Therapeutics has market cap of $139M and EV of -$18.4M.
Fate Therapeutics's trades at -1.3x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Fate Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fate Therapeutics has a P/E ratio of -0.8x.
See valuation multiples for Fate Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $139M | XXX | $139M | XXX | XXX | XXX |
| EV (current) | -$18.4M | XXX | -$18.4M | XXX | XXX | XXX |
| EV/Revenue | -1.9x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFate Therapeutics's last 12 month revenue growth is -58%
Fate Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.2M for the same period.
Fate Therapeutics's rule of 40 is -329% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fate Therapeutics's rule of X is -2020% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fate Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -58% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1875% | XXX | -1295% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | -329% | XXX | -1353% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2020% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 990% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1535% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fate Therapeutics acquired XXX companies to date.
Last acquisition by Fate Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Fate Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fate Therapeutics founded? | Fate Therapeutics was founded in 2007. |
| Where is Fate Therapeutics headquartered? | Fate Therapeutics is headquartered in United States of America. |
| How many employees does Fate Therapeutics have? | As of today, Fate Therapeutics has 181 employees. |
| Who is the CEO of Fate Therapeutics? | Fate Therapeutics's CEO is Dr. Bahram Valamehr, M.B.A.,PhD. |
| Is Fate Therapeutics publicy listed? | Yes, Fate Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Fate Therapeutics? | Fate Therapeutics trades under FATE ticker. |
| When did Fate Therapeutics go public? | Fate Therapeutics went public in 2013. |
| Who are competitors of Fate Therapeutics? | Similar companies to Fate Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fate Therapeutics? | Fate Therapeutics's current market cap is $139M |
| What is the current revenue of Fate Therapeutics? | Fate Therapeutics's last 12 months revenue is $9.8M. |
| What is the current revenue growth of Fate Therapeutics? | Fate Therapeutics revenue growth (NTM/LTM) is -58%. |
| What is the current EV/Revenue multiple of Fate Therapeutics? | Current revenue multiple of Fate Therapeutics is -1.9x. |
| Is Fate Therapeutics profitable? | Yes, Fate Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fate Therapeutics? | Fate Therapeutics's last 12 months EBITDA is -$185M. |
| What is Fate Therapeutics's EBITDA margin? | Fate Therapeutics's last 12 months EBITDA margin is -1875%. |
| What is the current EV/EBITDA multiple of Fate Therapeutics? | Current EBITDA multiple of Fate Therapeutics is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
